The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data

Type 2 diabetes (T2D) is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions. In a recent cardiovascular outcomes trial, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2018
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954590/
https://www.ncbi.nlm.nih.gov/pubmed/29922347
http://dx.doi.org/10.17925/EE.2018.14.1.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954590/
https://www.ncbi.nlm.nih.gov/pubmed/29922347
http://dx.doi.org/10.17925/EE.2018.14.1.17

Ejemplares similares